Syndesi Therapeutics

Recent Finacing

Series A

Recent Raise

$20.8M

Syndesi Therapeutics is a Belgian company developing SV2A modulators to treat cognitive impairment in Alzheimer's, dementias and schizophrenia, advancing compounds through clinical development under an exclusive UCB license.

Founded 2018

Vlaams-Brabant, Belgium

11-50

Private

syndesitherapeutics.com

Highlights

Focus Areas

Biotechnology

Health Care

Pharmaceutical

Recent Investors

N

Financials

$20.8M

Total Raised

1

Funding round

6

Investors

Team

Upgrade to view the team

See the team members at Syndesi Therapeutics.